Literature DB >> 12416605

Is response to prophylactic lithium a familial trait?

Paul Grof1, Anne Duffy, Patrizia Cavazzoni, Eva Grof, Julie Garnham, Marsha MacDougall, Claire O'Donovan, Martin Alda.   

Abstract

BACKGROUND: Selecting a drug according to the treatment response in a relative has been widely accepted advice in the management of mood disorders. However, this recommendation has not been adequately substantiated in the literature. We tested the hypothesis that response to long-term lithium treatment is a familial trait.
METHOD: We compared response to long-term lithium treatment in bipolar relatives of bipolar lithium responders and bipolar controls. Twenty-four relatives with bipolar disorder (as determined using the Schedule for Affective Disorders and Schizophrenia-Lifetime version [SADS-L] and Research Diagnostic Criteria [RDC]) were identified in families of 106 patients with lithium-responsive bipolar disorder. A consecutive series of 40 lithium-treated patients in a bipolar clinic (meeting RDC and DSM-IV criteria for bipolar disorder) served as a comparison group. Lithium response was evaluated on a rating scale reflecting the quality and quantity of available data.
RESULTS: The prevalence of unequivocal response among the relatives was 67%, as compared with the response rate of 35% in the comparison group (chi2 = 6.04, df = 1, p = .014).
CONCLUSION: This highly significant difference in response between relatives and the control group supports the view that the response to lithium prophylaxis clusters in families.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416605     DOI: 10.4088/jcp.v63n1013

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  95 in total

1.  The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.

Authors:  Thomas G Schulze; Martin Alda; Mazda Adli; Nirmala Akula; Raffaella Ardau; Elise T Bui; Caterina Chillotti; Sven Cichon; Piotr Czerski; Maria Del Zompo; Sevilla D Detera-Wadleigh; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Rebecca Hoban; Nakao Iwata; Layla Kassem; Tadafumi Kato; Sarah Kittel-Schneider; Sebastian Kliwicki; John R Kelsoe; Ichiro Kusumi; Gonzalo Laje; Susan G Leckband; Mirko Manchia; Glenda Macqueen; Takuya Masui; Norio Ozaki; Roy H Perlis; Andrea Pfennig; Paola Piccardi; Sara Richardson; Guy Rouleau; Andreas Reif; Janusz K Rybakowski; Johanna Sasse; Johannes Schumacher; Giovanni Severino; Jordan W Smoller; Alessio Squassina; Gustavo Turecki; L Trevor Young; Takeo Yoshikawa; Michael Bauer; Francis J McMahon
Journal:  Neuropsychobiology       Date:  2010-05-08       Impact factor: 2.328

Review 2.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

Review 3.  Genetics of bipolar disorder.

Authors:  Jordan W Smoller; Erica Gardner-Schuster
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

4.  Evidence towards RNA Binding Motif (RNP1, RRM) Protein 3 (RBM3) as a Potential Biomarker of Lithium Response in Bipolar Disorder Patients.

Authors:  Eleni Merkouri Papadima; Paola Niola; Carla Melis; Claudia Pisanu; Donatella Congiu; Cristiana Cruceanu; Juan Pablo Lopez; Gustavo Turecki; Raffaella Ardau; Giovanni Severino; Caterina Chillotti; Maria Del Zompo; Alessio Squassina
Journal:  J Mol Neurosci       Date:  2017-06-14       Impact factor: 3.444

Review 5.  Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.

Authors:  Gin S Malhi; Tim Outhred
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

Review 6.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

7.  Chronotype and cellular circadian rhythms predict the clinical response to lithium maintenance treatment in patients with bipolar disorder.

Authors:  Michael J McCarthy; Heather Wei; Caroline M Nievergelt; Andrea Stautland; Adam X Maihofer; David K Welsh; Paul Shilling; Martin Alda; Ney Alliey-Rodriguez; Amit Anand; Ole A Andreasson; Yokesh Balaraman; Wade H Berrettini; Holli Bertram; Kristen J Brennand; Joseph R Calabrese; Cynthia V Calkin; Ana Claasen; Clara Conroy; William H Coryell; David W Craig; Nicole D'Arcangelo; Anna Demodena; Srdjan Djurovic; Scott Feeder; Carrie Fisher; Nicole Frazier; Mark A Frye; Fred H Gage; Keming Gao; Julie Garnham; Elliot S Gershon; Kara Glazer; Fernando Goes; Toyomi Goto; Gloria Harrington; Petter Jakobsen; Masoud Kamali; Elizabeth Karberg; Marisa Kelly; Susan G Leckband; Falk Lohoff; Melvin G McInnis; Francis Mondimore; Gunnar Morken; John I Nurnberger; Sarah Obral; Ketil J Oedegaard; Abigail Ortiz; Megan Ritchey; Kelly Ryan; Martha Schinagle; Helle Schoeyen; Candice Schwebel; Martha Shaw; Tatyana Shekhtman; Claire Slaney; Emma Stapp; Szabolcs Szelinger; Bruce Tarwater; Peter P Zandi; John R Kelsoe
Journal:  Neuropsychopharmacology       Date:  2018-11-16       Impact factor: 7.853

8.  Predictors of lithium response in bipolar disorder.

Authors:  Sarah K Tighe; Pamela B Mahon; James B Potash
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

9.  Rapid cycling bipolar disorders in primary and tertiary care treated patients.

Authors:  Tomas Hajek; Margaret Hahn; Claire Slaney; Julie Garnham; Joshua Green; Martina Růzicková; Peter Zvolský; Martin Alda
Journal:  Bipolar Disord       Date:  2008-06       Impact factor: 6.744

10.  A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder.

Authors:  Roy H Perlis; Jordan W Smoller; Manuel A R Ferreira; Andrew McQuillin; Nick Bass; Jacob Lawrence; Gary S Sachs; Vishwajit Nimgaonkar; Edward M Scolnick; Hugh Gurling; Pamela Sklar; Shaun Purcell
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.